Clinical factors and the decision to transfuse chronic dialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 11, 2013, Pages 1942-1951

  Whitman, Cynthia B ^a,b   Shreay, Sanatan ^c   Gitlin, Matthew ^c   van Oijen, Martijn G H ^d,e   Spiegel, Brennan M R ^b,d,e,f  

^a Department of Research ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ADAPTIVE CHOICE BASED CONJOINT ANALYSIS; ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; DIALYSIS; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; FUNCTIONAL STATUS; HEALTH SURVEY; HUMAN; MALE; NEPHROLOGIST; OCCULT BLOOD; PREDICTION; QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; ANEMIA; BIOLOGICAL MARKERS; COMORBIDITY; DECISION SUPPORT TECHNIQUES; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE SURVEYS; HEALTH STATUS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84887285863     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00160113     Document Type: Article

References (46)

1. Muirhead N, Keown PA, Churchill DN, Poulin-Costello M, Gantotti S, Lei L, Gitlin M, Mayne TJ: Dialysis patients treated with Epoetin a show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial [published online ahead of print December 2, 2010]. Hemodial Int 10.1111/j.1542-4758.2010.00508
2. Lasch KF, Evans CJ, Schatell D: A qualitative analysis of patientreported symptoms of anemia. Nephrol Nurs J 36: 621-633, 2009
3. Keown PA, Churchill DN, Poulin-Costello M, Lei L, Gantotti S, Agodoa I, Gitlin M, Gandra SR, Mayne TJ: Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 14: 168-173, 2010
4. Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, Mayne TJ: Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 55: 535-548, 2010
5. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N: Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int Suppl 87: S6-S11, 2003
6. Collins A, Ellefson J: Association between hematocrit level and mortality in hemodialysis patients. Case study of the anemic patient. Nephrol Nurs J 27: 233-236, 2000
7. Collins AJ, Li S, St PeterW, Ebben J, Roberts T, Ma JZ, ManningW: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473, 2001
8. Li S, Collins AJ: Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65: 626-633, 2004
9. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ: Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121-132, 2004
10. Akizawa T, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, Saito A, Akiba T, Hirakata H, Fukuhara S, Morita S, Hiroe M, Hada Y, Suzuki M, Akaishi M, IwasakiM, Tsubakihara Y; KRN321 STUDY Group: Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: A randomized controlled study. Ther Apher Dial 15: 431-440, 2011
11. Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335, 2000
12. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78, 1987
13. Drüeke TB, Parfrey PS: Summary of the KDIGO guideline on anemia and comment: Reading Between the (guide)line(s). Kidney Int 82: 952-960, 2012
14. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
15. Hedley BD, Allan AL, Xenocostas A: The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 17: 6373-6380, 2011
16. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK: Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 74: 782-790, 2008
17. Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege A-M, Fishbane S; PEARL Study Groups: Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 368: 320-332, 2013
18. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesisstimulating agents-time for a reevaluation. N Engl J Med 362: 189-192, 2010
19. Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA: Effect of hemoglobin target on progression of kidney disease: A secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 60: 390-401, 2012
20. RosnerMH, BoltonWK: The mortality risk associatedwith higher hemoglobin: Is the therapy to blame? Kidney Int 74: 695-697, 2008
21. Singh AK, Szczech L, Tang KL, Barnhart HX, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
22. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
23. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB; RED-HF Committees and Investigators: Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF): A phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11: 785-801, 2010
24. Amgen, Inc.: Epogen (Epoetin Alfa) Package Insert, Thousand Oaks, CA, Amgen, Inc., 2012
25. Medicare Program: End-Stage Renal Disease Prospective Payment System, Federal Registry, 2010, pp 49030-49078. Available at: http://www.gpo.gov/fdsys/pkg/FR-2010-08-12/html/2010-18466. htm
26. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J: Conjoint analysis applications in health-a checklist: A report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 14: 403-413, 2011
27. Cunningham CE, Deal K, Chen Y: Adaptive choice-based conjoint analysis: A new patient-centered approach to the assessment of health service preferences. Patient 3: 257-273, 2010
28. Gustafsson A, Herrmann A, Huber F: Conjoint Measurement: Methods and Applications, Berlin, Springer Verlag, 2007
29. Orme B: Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research, 2nd Ed., Madison, WI, Research Publishers LLC, 2010, pp 64-65
30. Johnson RM, Orme B: How Many Questions Should You Ask in Choice-Based Conjoint Studies?, Sequim, WA, Sawtooth Software Inc., 1996
31. Zimmerman TM, Clouth J, Elosge M, Heurich M, Schneider E, Wilhelm S, Wilfrath A: Patient preferences for outcomes of depression treatment in Germany: A choice-based conjoint analysis study. J Affect Disord 148: 210-219, 2013
32. KievitW, vanHulst L, van Riel P, Fraenkel L: Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: Results from a choice-based conjoint analysis. Arthritis Care Res (Hoboken) 62: 842-847, 2010
33. Bederman SS, Mahomed NN, Kreder HJ, McIsaacWJ, Coyte PC, Wright JG: In the eye of the beholder: Preferences of patients, family physicians, and surgeons for lumbar spinal surgery. Spine 35: 108-115, 2010
34. Porzsolt F, Clouth J, Deutschmann M, Hippler HJ: Preferences of diabetes patients and physicians: A feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes 8: 125, 2010
35. Abbes Orabi N, Vanwymersch T, Paterson HM, Mauel E, Jamart J, Crispin B, Kartheuser A: Total perineal reconstruction after abdominoperineal excision for rectal cancer: Long-term results of dynamic graciloplasty with Malone appendicostomy. Colorectal Dis 13: 406-413, 2011
36. van Lieshout EJ, de Vos R, Binnekade JM, de Haan R, Schultz MJ, Vroom MB: Decision making in interhospital transport of critically ill patients: National questionnaire survey among critical care physicians. Intensive Care Med 34: 1269-1273, 2008
37. Beusterien KM, Dziekan K, Flood E, Harding G, Jordan JC: Understanding patient preferences for HIV medications using adaptive conjoint analysis: Feasibility assessment. Value Health 8: 453-461, 2005
38. KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47: S11-S145, 2006
39. Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR: Conjoint analysis applications in health-howare studies being designed and reported?: An update on current practice in the published literature between 2005 and 2008. Patient 3: 249-256, 2010
40. Desai AA, Bolus R, Nissenson A, ChertowGM, Bolus S, Solomon MD, Khawar OS, Talley J, SpiegelBM: Is there "cherry picking" in the ESRD Program? Perceptions from a Dialysis Provider Survey. Clin J Am Soc Nephrol 4: 772-777, 2009
41. Desai AA, Bolus R, Nissenson A, Bolus S, Solomon MD, Khawar O, Gitlin M, Talley J, Spiegel BM: Identifying best practices in dialysis care: Results of cognitive interviews and a national survey of dialysis providers. Clin J Am Soc Nephrol 3: 1066-1076, 2008
42. USRDS: USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011
43. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M: Comparison of vignettes, standardized patients, and chart abstraction: A prospective validation study of 3 methods for measuring quality. JAMA 283: 1715-1722, 2000
44. Luck J, Peabody JW, Dresselhaus TR, Lee M, Glassman P: How well does chart abstraction measure quality? A prospective comparison of standardized patients with the medical record. Am J Med 108: 642-649, 2000
45. Peabody JW, Luck J, Glassman P, Jain S, Hansen J, SpellM, Lee M: Measuring the quality of physician practice by using clinical vignettes: A prospective validation study. Ann Intern Med 141: 771-780, 2004
46. Carroll RG: Evaluation of vignette-type examination items for testing medical physiology. Am J Physiol 264: S11-S15, 1993